Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis.
about
Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancerInteraction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailabilityLoss of SPARC in bladder cancer enhances carcinogenesis and progression.Differential roles of uPAR in peritoneal ovarian carcinomatosisThe role of SPARC in the TRAMP model of prostate carcinogenesis and progression.SPARC is a key regulator of proliferation, apoptosis and invasion in human ovarian cancer.SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response.SPARC overexpression suppresses radiation-induced HSP27 and induces the collapse of mitochondrial Δψ in neuroblastoma cellsRelationship and prognostic significance of SPARC and VEGF protein expression in colon cancer.SPARC overexpression inhibits cell proliferation in neuroblastoma and is partly mediated by tumor suppressor protein PTEN and AKT.SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations.Targeting SPARC by lentivirus-mediated RNA interference inhibits cervical cancer cell growth and metastasis.Augmented osteolysis in SPARC-deficient mice with bone-residing prostate cancer.Aberrant methylation of the SPARC gene promoter and its clinical implication in gastric cancer.Anti-cancer role of SPARC, an inhibitor of adipogenesisAssessment of selected cytokines, proteins, and growth factors in the peritoneal fluid of patients with ovarian cancer and benign gynecological conditions.A peptide of SPARC interferes with the interaction between caspase8 and Bcl2 to resensitize chemoresistant tumors and enhance their regression in vivoSPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk.Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer.SPARC Regulates Transforming Growth Factor Beta Induced (TGFBI) Extracellular Matrix Deposition and Paclitaxel Response in Ovarian Cancer Cells.SPARC ameliorates ovarian cancer-associated inflammation.Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity.Aberrant promoter methylation of SPARC in ovarian cancerThe role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host.Glycemic control prevents microvascular remodeling and increased tone in type 2 diabetes: link to endothelin-1.SPARC: a matricellular regulator of tumorigenesis.Roles of SPARC in urothelial carcinogenesis, progression and metastasis.SPARC: a key player in the pathologies associated with obesity and diabetes.The regulatory function of SPARC in vascular biology.Stromal expression of SPARC in pancreatic adenocarcinoma.Role of SPARC in bone remodeling and cancer-related bone metastasis.Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition.Molecular mechanisms underlying the divergent roles of SPARC in human carcinogenesis.Secreted Protein Acidic and Rich in Cysteine (SPARC) Mediates Metastatic Dormancy of Prostate Cancer in Bone.Molecular mechanisms underlying postoperative peritoneal tumor dissemination may differ between a laparotomy and carbon dioxide pneumoperitoneum: a syngeneic mouse model with controlled respiratory support.The copper binding domain of SPARC mediates cell survival in vitro via interaction with integrin beta1 and activation of integrin-linked kinase.Differential effects of diet-induced dyslipidemia and hyperglycemia on mesenteric resistance artery structure and function in type 2 diabetes.CpG island methylation profile of pancreatic intraepithelial neoplasia.Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.SPARC modulates the proliferation of stromal but not melanoma cells unless endogenous SPARC expression is downregulated.
P2860
Q24623746-155BC601-3EC6-4937-80EF-A37AAEAE6323Q29012696-F8BBB0FE-7842-4E7D-B787-1C7093EE5CA9Q30422650-A6CB3775-4B66-49B6-B9C1-78CB39858B26Q30426956-73305897-3E3D-4FF4-BFE8-A48586860250Q30448744-3C17C556-B7C9-402D-8C52-5DC2FBD2BE85Q31083068-8F9FDFD3-2AFF-4187-A427-15E2ACAF7CCBQ33331870-1E48B967-65FD-4BFC-AB57-E1859A8A6F0BQ33751169-8702FCBB-907B-4DB8-A5CF-726D55D04035Q33955148-E4BBCD84-D35D-4E22-B384-9DD1C5122709Q34261684-4F40C56E-B996-4F31-9F93-6B5D8A9EAA2CQ34410598-B5ECC5D7-039B-4A13-89EB-E9CC8B5389F1Q34439076-1DF09B05-66F5-48DE-B910-0B96F7798193Q34497987-DD918DF5-9C2E-4E6B-A558-9FBBA1B6ED8FQ34719794-78D96F35-C072-4069-9F0F-552E37E926D4Q35116107-8171C84C-619D-41EC-823F-838B350E0CA9Q35142408-8C7A1106-6A56-42D1-8398-C6499B16053BQ35499905-819E22AA-FF8B-40C8-9090-55EC9E325A30Q35647529-689161E0-CA32-4A2B-9A1C-57D7EA57A625Q35781408-481BEE41-BBB8-4CE3-84BA-09F098DB48C9Q36131297-68A28638-5697-4D35-A9CD-838E24B6E767Q36897774-20741874-6BC0-4147-8C9E-89B0F880A2E4Q37004638-334061FF-3EAD-44E7-A8AD-3999A1570B34Q37073261-7A1316BD-F609-49BF-95FC-55FFA66B5CA2Q37155625-7658E108-39D7-4A7F-BEEB-C5AEA257D838Q37232993-99F4788F-5471-4F3D-A1DB-0A26CE4D9872Q37610020-CC8A71A9-F551-4AE1-BA03-8802F4D677E1Q37687199-7E150973-B941-463D-93C4-4E535EC94977Q37701264-FF3E2B1D-AB4F-429B-AB92-16B0025D48CFQ37913130-9FF689CF-134B-4A1C-BBBE-CDF505E2A7B4Q38108253-791B1E1E-C6AD-4E6C-8C74-4B53F3E50D34Q38137862-67E67D15-0DA8-4264-B7BF-3980D3809565Q38172849-77F69F15-6EB7-4172-95C0-AE11B52083C9Q38199932-0E355F2E-A3BA-4448-AF47-EB44C425997BQ38757854-7587E070-1B3A-4F6C-A023-EFDF59A3B80AQ39962035-10EDA9CB-E9EB-419F-8E68-0B24CE21C7AAQ41889041-FFD12CD4-7B37-4314-9760-4AB314D2A354Q42012334-5056B1A0-97BD-44D3-90F1-D7BBD944C975Q42053166-BA1B175E-BB2B-4C4F-8E43-59E56AEEB3BEQ43287051-4153C6C5-4FE1-412B-8415-8C315C7CF490Q46866346-5203B4D7-2F1F-497D-BA7F-9A2DE61C3FD1
P2860
Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Absence of host-secreted prote ...... toneal ovarian carcinomatosis.
@ast
Absence of host-secreted prote ...... toneal ovarian carcinomatosis.
@en
type
label
Absence of host-secreted prote ...... toneal ovarian carcinomatosis.
@ast
Absence of host-secreted prote ...... toneal ovarian carcinomatosis.
@en
prefLabel
Absence of host-secreted prote ...... toneal ovarian carcinomatosis.
@ast
Absence of host-secreted prote ...... toneal ovarian carcinomatosis.
@en
P2860
P1476
Absence of host-secreted prote ...... toneal ovarian carcinomatosis.
@en
P2093
Kouros Motamed
Neveen Said
P2860
P304
P356
10.1016/S0002-9440(10)61255-2
P407
P577
2005-12-01T00:00:00Z